Cargando…
Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elmer Press
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737043/ https://www.ncbi.nlm.nih.gov/pubmed/26858805 http://dx.doi.org/10.14740/jocmr2417wc1 |
| _version_ | 1782413406896128000 |
|---|---|
| author | Iizuka, Takashi Iemitsu, Kotaro Takihata, Masahiro Takai, Masahiko Nakajima, Shigeru Minami, Nobuaki Umezawa, Shinichi Kanamori, Akira Takeda, Hiroshi Kawata, Takehiro Ito, Shogo Kikuchi, Taisuke Amemiya, Hikaru Kaneshiro, Mizuki Mokubo, Atsuko Takuma, Tetsuo Machimura, Hideo Tanaka, Keiji Asakura, Taro Kubota, Akira Aoyagi, Sachio Hoshino, Kazuhiko Ishikawa, Masashi Matsuzawa, Yoko Obana, Mitsuo Sasai, Nobuo Kaneshige, Hideaki Minagawa, Fuyuki Saito, Tatsuya Shinoda, Kazuaki Miyakawa, Masaaki Tanaka, Yasushi Terauchi, Yasuo Matsuba, Ikuro |
| author_facet | Iizuka, Takashi Iemitsu, Kotaro Takihata, Masahiro Takai, Masahiko Nakajima, Shigeru Minami, Nobuaki Umezawa, Shinichi Kanamori, Akira Takeda, Hiroshi Kawata, Takehiro Ito, Shogo Kikuchi, Taisuke Amemiya, Hikaru Kaneshiro, Mizuki Mokubo, Atsuko Takuma, Tetsuo Machimura, Hideo Tanaka, Keiji Asakura, Taro Kubota, Akira Aoyagi, Sachio Hoshino, Kazuhiko Ishikawa, Masashi Matsuzawa, Yoko Obana, Mitsuo Sasai, Nobuo Kaneshige, Hideaki Minagawa, Fuyuki Saito, Tatsuya Shinoda, Kazuaki Miyakawa, Masaaki Tanaka, Yasushi Terauchi, Yasuo Matsuba, Ikuro |
| author_sort | Iizuka, Takashi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4737043 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Elmer Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-47370432016-02-08 Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study Iizuka, Takashi Iemitsu, Kotaro Takihata, Masahiro Takai, Masahiko Nakajima, Shigeru Minami, Nobuaki Umezawa, Shinichi Kanamori, Akira Takeda, Hiroshi Kawata, Takehiro Ito, Shogo Kikuchi, Taisuke Amemiya, Hikaru Kaneshiro, Mizuki Mokubo, Atsuko Takuma, Tetsuo Machimura, Hideo Tanaka, Keiji Asakura, Taro Kubota, Akira Aoyagi, Sachio Hoshino, Kazuhiko Ishikawa, Masashi Matsuzawa, Yoko Obana, Mitsuo Sasai, Nobuo Kaneshige, Hideaki Minagawa, Fuyuki Saito, Tatsuya Shinoda, Kazuaki Miyakawa, Masaaki Tanaka, Yasushi Terauchi, Yasuo Matsuba, Ikuro J Clin Med Res Correction Elmer Press 2016-03 2016-01-26 /pmc/articles/PMC4737043/ /pubmed/26858805 http://dx.doi.org/10.14740/jocmr2417wc1 Text en Copyright 2016, Iizuka et al. http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| spellingShingle | Correction Iizuka, Takashi Iemitsu, Kotaro Takihata, Masahiro Takai, Masahiko Nakajima, Shigeru Minami, Nobuaki Umezawa, Shinichi Kanamori, Akira Takeda, Hiroshi Kawata, Takehiro Ito, Shogo Kikuchi, Taisuke Amemiya, Hikaru Kaneshiro, Mizuki Mokubo, Atsuko Takuma, Tetsuo Machimura, Hideo Tanaka, Keiji Asakura, Taro Kubota, Akira Aoyagi, Sachio Hoshino, Kazuhiko Ishikawa, Masashi Matsuzawa, Yoko Obana, Mitsuo Sasai, Nobuo Kaneshige, Hideaki Minagawa, Fuyuki Saito, Tatsuya Shinoda, Kazuaki Miyakawa, Masaaki Tanaka, Yasushi Terauchi, Yasuo Matsuba, Ikuro Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title | Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title_full | Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title_fullStr | Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title_full_unstemmed | Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title_short | Correction: Efficacy and Safety of Ipragliflozin in Japanese Patients With Type 2 Diabetes: Interim Outcome of the ASSIGN-K Study |
| title_sort | correction: efficacy and safety of ipragliflozin in japanese patients with type 2 diabetes: interim outcome of the assign-k study |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737043/ https://www.ncbi.nlm.nih.gov/pubmed/26858805 http://dx.doi.org/10.14740/jocmr2417wc1 |
| work_keys_str_mv | AT iizukatakashi correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT iemitsukotaro correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT takihatamasahiro correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT takaimasahiko correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT nakajimashigeru correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT minaminobuaki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT umezawashinichi correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kanamoriakira correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT takedahiroshi correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kawatatakehiro correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT itoshogo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kikuchitaisuke correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT amemiyahikaru correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kaneshiromizuki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT mokuboatsuko correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT takumatetsuo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT machimurahideo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT tanakakeiji correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT asakurataro correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kubotaakira correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT aoyagisachio correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT hoshinokazuhiko correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT ishikawamasashi correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT matsuzawayoko correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT obanamitsuo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT sasainobuo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT kaneshigehideaki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT minagawafuyuki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT saitotatsuya correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT shinodakazuaki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT miyakawamasaaki correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT tanakayasushi correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT terauchiyasuo correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy AT matsubaikuro correctionefficacyandsafetyofipragliflozininjapanesepatientswithtype2diabetesinterimoutcomeoftheassignkstudy |